6例非酒精性脂肪性肝病小鼠肠道B细胞的变化

doi:10.6040/j.issn.1671-7554.0.2022.0686

摘要/Abstract

摘要： 目的探索非酒精性脂肪性肝病(NAFLD)小鼠肠道B细胞的变化。方法将12只雄性C57BL/6J小鼠随机分为实验组和对照组,每组6只。实验组喂以45%高脂肪饮食诱导发生NAFLD,对照组喂以正常饮食。16周后处死小鼠,留取两组肝脏、小肠黏膜、结肠黏膜、肠系膜淋巴结(MLN)、派氏结(PP)及小肠内容物。采用苏木精-伊红染色法确认实验组发生NAFLD,采用免疫组织化学染色法及实时定量PCR法检测小肠及结肠黏膜中B细胞的分布和含量。采用流式细胞术分析MLN和PP中B细胞比例。采用酶联免疫法检测小肠内容物sIgA的水平。采用免疫磁珠法分选MLN中的B细胞进行体外培养,加入脂多糖(LPS)或抗CD40和抗IgM(BCR)刺激,采用细胞因子流式技术法检测培养液上清白介素-6、白介素-10及肿瘤坏死因子-α的水平。结果实验组和对照组小肠及结肠的B细胞散在分布于固有层中。与对照组相比,实验组MLN和PP中B细胞比例增多(P_MLN-B细胞=0.025,P_PP-B细胞=0.004)。实验组小肠内容物中sIgA的含量较对照组明显升高(P=0.042),并且其PP中IgA+B细胞比例升高(P=0.023)。体外实验显示,实验组MLN中的B细胞接受刺激后分泌IL-6增多(P_LPS<0.001,P_BCR=0.003)。结论 NAFLD小鼠PP及MLN中B细胞比例增多,不仅小肠内sIgA含量增多,并且其MLN中B细胞接受刺激后分泌促炎性IL-6增多。

关键词: 非酒精性脂肪性肝病, B细胞, 肠道, 肠肝轴, 炎症因子

Abstract: Objective To investigate the changes of intestinal B lymphocytes in mice with non-alcoholic fatty liver disease(NAFLD)induced by high fat diet. Methods A total of 12 male C57BL/6J mice were randomly divided into the experimental group and control group, with 6 in either group. The experimental group was fed with 45% high fat diet, while the control group with normal diet. After 16 weeks, the mice were killed to collect liver, small intestine mucosa, colon mucosa, mesenteric lymph nodes(MLN), Peyers patches(PP)and small intestine contents. Hepatic steatosis in experimental group was confirmed with hematoxylin and eosin(HE)staining. The distribution and expression of B cells in small intestine and colon mucosa were detected with immunohistochemical staining and real-time quantitative PCR, respectively. Proportion of B and T lymphocytes in the MLN and PP were analyzed with flow cytometry. The sIgA level in the small intestinal contents was detected with enzyme linked immunosorbent assay(ELISA). B lymphocytes were enriched with a magnetic-activated cell sorting method and cultured in vitro with or without the stimulation of lipopolysaccharide(LPS)or anti-CD40/IgM(BCR). The levels of IL-6, IL-10 and TNF-α in the cultural supernatants were monitored with cytometric bead arrays(CBA). Results B lymphocytes scattered throughout the lamina in both groups. The proportion of B lymphocytes was increased significantly in MLN and PP in experimental group than in control group(P_MLN-B=0.025, P_PP-B=0.004). The experimental group had higher level of sIgA in the small intestinal contents(P=0.042), which was in line with the higher proportion of IgA+ B lymphocytes in the PP(P=0.023). B lymphocytes in MLN in the experimental group secreted more IL-6 upon the stimulation of LPS or anti-CD40/IgM(BCR)(P_LPS<0.001, P_BCR=0.003)than in the control group. Conclusion Proportion of B lymphocytes in PP and MLN increased significantly in NAFLD mice. Small intestine secreted higher level of sIgA, and B lymphocytes in MLN produced more IL-6 upon stimulation in NAFLD mice.

Key words: Non-alcoholic fatty liver disease, B lymphocyte, Gut, Gut-liver axis, Inflammatory cytokine

中图分类号:

R575

张凤,吴哲,徐俊,刘玉兰. 6例非酒精性脂肪性肝病小鼠肠道B细胞的变化[J]. 山东大学学报 (医学版), 2022, 60(9): 67-73.

ZHANG Feng, WU Zhe, XU Jun, LIU Yulan. Changes of intestinal B lymphocytes in 6 mice with non-alcoholic fatty liver disease[J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 67-73.

参考文献

[1] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology, 2019, 69(6): 2672-2682.
[2] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4): 862-873.
[3] Zhu J, Xu D, Yang R, et al. The triglyceride glucose index(TyG)and CDKAL1 gene rs10946398 SNP are associated with NAFLD in Chinese adults[R]. Minerva Endocrinol, 2020. doi: 10.23736/S0391-1977.20.03273-3.
[4] Day CP, James OF. Steatohepatitis: a tale of two “hits” ?[J]. Gastroenterology, 1998, 114(4): 842-845.
[5] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846.
[6] Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol, 2021, 19(1): 55-71.
[7] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature[J]. Int J Mol Sci, 2019, 20(2): E395.
[8] Ahluwalia B, Magnusson MK, Öhman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad[J]. Scand J Gastroenterol, 2017, 52(11): 1185-1193.
[9] Tourkochristou E, Triantos C, Mouzaki A. The influence of nutritional factors on immunological outcomes[J]. Front Immunol, 2021, 12: 665968. doi: 10.3389/fimmu.2021.665968.
[10] Marshall JC. The gut as a potential trigger of exercise-induced inflammatory responses[J]. Can J Physiol Pharmacol, 1998, 76(5): 479-484.
[11] Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota[J]. Gastroenterol Rep(Oxf), 2019, 7(1): 3-12.
[12] Volynets V, Küper MA, Strahl S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease(NAFLD)[J]. Dig Dis Sci, 2012, 57(7): 1932-1941.
[13] Briskey D, Heritage M, Jaskowski LA, et al. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease[J]. Therap Adv Gastroenterol, 2016, 9(4): 463-472.
[14] Castoldi A, Favero de Aguiar C, Moraes-Vieira PM, et al. They must hold tight: junction proteins, microbiota and immunity in intestinal mucosa[J]. Curr Protein Pept Sci, 2015, 16(7): 655-671.
[15] Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease[J]. Sci Rep, 2015, 5: 8096. doi: 10.1038/srep08096.
[16] Ferro D, Baratta F, Pastori D, et al. New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress[J]. Nutrients, 2020, 12(9): E2762.
[17] Kolodziejczyk AA, Zheng D, Shibolet O, et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med, 2019, 11(2): e9302.
[18] Mörbe UM, Jrgensen PB, Fenton TM, et al. Human gut-associated lymphoid tissues(GALT); diversity, structure, and function[J]. Mucosal Immunol, 2021, 14(4): 793-802.
[19] Muniz LR, Knosp C, Yeretssian G. Intestinal antimicrobial peptides during homeostasis, infection, and disease[J]. Front Immunol, 2012, 3: 310. doi: 10.3389/fimmu.2012.00310.
[20] Chairatana P, Nolan EM. Defensins, lectins, mucins, and secretory immunoglobulin a: microbe-binding biomolecules that contribute to mucosal immunity in the human gut[J]. Crit Rev Biochem Mol Biol, 2017, 52(1): 45-56.
[21] Mohamad Nor MH, Ayob N, Mokhtar NM, et al. The effect of probiotics(MCP® BCMC® strains)on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease[J]. Nutrients, 2021, 13(9): 3192.
[22] Palm NW, de Zoete MR, Cullen TW, et al. Immunoglobulin a coating identifies colitogenic bacteria in inflammatory bowel disease[J]. Cell, 2014, 158(5): 1000-1010.
[23] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease(NAFLD)- pathogenesis, classification, and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev, 2017, 49(2): 197-211.
[24] Akbari R, Behdarvand T, Afarin R, et al. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis[J]. BMC Pharmacol Toxicol, 2021, 22(1): 53.
[25] Van Herck MA, Weyler J, Kwanten WJ, et al. The differential roles of T cells in non-alcoholic fatty liver disease and obesity[J]. Front Immunol, 2019, 10: 82. doi: 10.3389/fimmu.2019.00082.
[26] Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies[J]. Nat Med, 2011, 17(5): 610-617.
[27] DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile[J]. PNAS, 2013, 110(13): 5133-5138.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed